{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:00Z","timestamp":1790668500742,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"DOI":"10.1007\/s00044-026-03620-8","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:00:17Z","timestamp":1790665217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baxdrostat (Baxfendy\u00ae), a first-in-class aldosterone synthase inhibitor approved for adults with uncontrolled hypertension"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-6199","authenticated-orcid":false,"given":"Ahmed R.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5652","authenticated-orcid":false,"given":"Longqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"5","key":"3620_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2213169.","journal-title":"N Engl J Med"},{"issue":"1","key":"3620_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","volume":"69","author":"K Bogman","year":"2017","unstructured":"Bogman K, Schwab D, Delporte ML, Palermo G, Amrein K, Mohr S, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69(1):189\u201396. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07716.","journal-title":"Hypertension"},{"issue":"3","key":"3620_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40256-024-00713-w","volume":"25","author":"J Huston","year":"2025","unstructured":"Huston J, Orey D, Kumar A, Ashchi A, Ashchi A, Berner J, et al. Clinical pharmacokinetics and pharmacodynamics of baxdrostat. Am J Cardiovasc Drugs. 2025;25(3):329\u201336. https:\/\/doi.org\/10.1007\/s40256-024-00713-w.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"14","key":"3620_CR4","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393(14):1363\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2507109.","journal-title":"N Engl J Med"},{"issue":"1","key":"3620_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","volume":"46","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46(1):108\u201318. https:\/\/doi.org\/10.1038\/s41440-022-01070-4.","journal-title":"Hypertens Res"},{"issue":"20","key":"3620_CR6","doi-asserted-by":"publisher","first-page":"8054","DOI":"10.1021\/acs.jmedchem.5b00851","volume":"58","author":"RE Martin","year":"2015","unstructured":"Martin RE, Aebi JD, Hornsperger B, Krebs HJ, Kuhn B, Kuglstatter A, et al. Discovery of 4-aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: In vivo evaluation in rodents and cynomolgus monkeys. J Med Chem. 2015;58(20):8054\u201365. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00851.","journal-title":"J Med Chem"},{"issue":"4","key":"3620_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/cpdd.1371","volume":"13","author":"MW Freeman","year":"2024","unstructured":"Freeman MW, Halvorsen YD, Bond M, Murphy B, Isaacsohn J. Results from a phase 1 study assessing the pharmacokinetics of the aldosterone synthase Inhibitor baxdrostat in participants with varying degrees of renal function. Clin Pharmacol Drug Dev. 2024;13(4):410\u20138. https:\/\/doi.org\/10.1002\/cpdd.1371.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10532","key":"3620_CR8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","volume":"407","author":"M Azizi","year":"2026","unstructured":"Azizi M, Brown JM, Dwyer JP, Flack JM, Jones ESW, Kurlyandskaya R, et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10532):988\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(25)02549-8.","journal-title":"Lancet"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03620-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:00:17Z","timestamp":1790665217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03620-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":8,"alternative-id":["3620"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03620-8","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"19 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}